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Background: Maternal colonization of Group B streptococci (GBS) during pregnancy is
an important risk factor for neonatal morbidity and mortality. The aim of this study was
to determine the prevalence and serotype distribution of GBS isolated from a cohort of
pregnant women in the Western Cape, South Africa.
Methods: Two ano-vaginal swabs were collected from 301 women at 28–37 weeks of
gestation. Participants were recruited from four different antenatal clinics in the Western
Cape, South Africa. GBS were detected by culture and PCR and serotypes confirmed
by latex agglutination tests. Antibiotic sensitivity was performed using disc diffusion.
Results: The GBS colonization rate was 16.6%. Serotype distribution revealed serotype
V as the predominant serotype (66.67%) followed by serotype III (21.05%). Serotypes
Ia, II, IV, and IX constituted 1.75% each and 3 GBS isolates were non-typeable.
Serotype V demonstrated resistance to most of the antibiotics tested, while serotype
III demonstrated better susceptibility, except for tetracycline. No significant differences
were observed for GBS colonization or serotype distribution according to HIV status.
Conclusion: Predominating serotypes differed from those previously reported from
other regions in South Africa. Global surveillance of serotype distribution plays an
important role in informing vaccine development and antibiotic prophylaxis.
Keywords: group B Streptococcus, colonization and serotypes, pregnancy outcomes, antibiotic sensitivity, South
Africa
INTRODUCTION
Group B Streptococci (GBS) or Streptococcus agalactiae,may exist as part of the normal microbiota
in the female genital tract and anal areas of healthy adults, with the gastrointestinal tract serving as
the natural reservoir and source of vaginal colonization (1).
Maternal GBS colonization may result in pregnancy-associated conditions including urinary
tract infection, bacteremia, chorioamnionitis, postpartum endometritis, preterm labor (PTL),
preterm rupture of membranes (PROM) and perinatal transmission of the organism (1).
Intrauterine infection has been associated with the ability of GBS to ascend from the lower genital
tract and colonize the upper genital tract (2).
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GBS infection in the newborn remains the foremost cause
of neonatal morbidity and mortality globally, despite a recent
decline in occurrence (3) with the highest incidence of invasive
disease occurring in low-middle income regions such as in
Southern Africa (4). It presents as early-onset disease (EOD)
within 0–6 days of birth, or late-onset disease (LOD) after 7–
90 days (5). Maternal colonization has been described as a
prerequisite for EOD and a risk factor for LOD. Transmission
from mother to infant is thought to take place vertically through
aspiration of infected amniotic fluid or colonization of the
newborn during passage through the birth canal (5).
Intrapartum colonization is strongly associated with early
onset GBS sepsis, resulting in ∼4% of reported fatalities and
serious morbidities including sepsis, pneumonia, meningitis,
illness, and death in infants, along with long-term disabilities
(4, 6). Other well-established risk factors for early-onset invasive
GBS in newborns include rupture of membranes for more than
18 h before delivery, fever in the mother during labor, preterm
delivery and a history of GBS disease in previous infants.
The etiology of LOD is not as well-understood as EOD and
may involve community or nosocomial acquisition (7). However,
there is evidence that in several infants with LOD, the GBS
causing the infection share identical serotypes as the GBS isolated
from their mothers, suggesting a maternal source (7).
Intrapartum antibiotics are known to reduce EOD in many
countries (5), but in underdeveloped countries, particularly in
Africa where the prevalence rates are the highest, resources are
limited and hinder the implementation thereof. However, the
true burden of GBS colonization in many countries is not known,
and the current existing information shows great variation in the
colonization rates and serotype distribution in different parts of
the world, thus hampering the production of a suitable vaccine.
For the above reasons, the Centres for Disease Control and
Prevention (8) recommended that all pregnant women at 35–37
weeks gestation should be screened for GBS colonization using
vaginal-rectal specimens in order to decrease the morbidity and
mortality of GBS-associated neonatal disease. An understanding
of the global variations of GBS colonization and serotype
prevalence may be achieved through the study of more regions
across continents, thus providing the information needed to
inform the development of suitable vaccines. To this end, the
present study focused on a cohort of women in theWestern Cape,
South Africa, with the aim of establishing their GBS colonization
rates and predominant serotypes.
MATERIALS AND METHODS
Study Population
This study included 301 women at 28–37 weeks of gestation,
recruited from four antenatal clinics stationed in Mowbray,
Mitchells Plain, Guguletu, and Khayelitsha in the Western Cape,
South Africa. The participants were from lower socioeconomic
groups, representative of two different ethnic groups, namely,
black, and mixed-race groups. Patient details were captured in
Abbreviations: EOD, Early Onset Disease; GBS, Group B Streptococcus; LOD, late
onset disease.
a brief questionnaire to which a sample number was assigned to
ensure anonymity.
Excluded from the study were women who reported bacterial
infections for which antimicrobials were administered within 2
weeks prior to recruitment. Also excluded were those with any
reported condition for which clinical vaginal sampling may be
contraindicated.
Ethical Considerations
The content and objectives of the study were explained to the
participants and their consent obtained by signature on the
appropriate consent forms. Ethics approval for this study was
obtained from the human ethics committee of the University
of the Western Cape (UWC). The study complied with the
declaration of Helsinki (9).
Sample Collection
A vaginal and anorectal swab were collected from each patient
by trained nurses, using 2 separate sterile cotton-tipped swabs.
Vaginal swabs were collected by inserting the swab about 3 cm
into the vaginal wall and rotating the swab circumferentially.
Anorectal swabs were collected by swabbing through the anal
sphincter. Swabs were transported to the laboratory in carefully
labeled liquid Amies with charcoal medium (Sterilin, 18114CST,
Italy) and processed within 4 h of collection.
Sample Processing
Culture
Samples were inoculated in the order of first streaking onto
enriched blood supplemented CNAgar (colistin nalidixic agar,
Becton Dickinson, 63954, Bio-Rad Laboratories) followed by
inoculation in enriched broth (Todd-Hewitt Broth) and selective
broth (Todd–Hewitt broth supplemented with gentamicin: 8 µg
per milliliter and nalidixic acid: 15 µg per milliliter). The agar
and broths were then incubated at 37◦C for 24 h (h) in order to
ensure optimal recovery of GBS. Media showing no growth after
24 h were incubated for a further 24 h before being declared as
negative for growth. Culture purity was confirmed by subculture
onto 5% sheep blood agar and microscopy using Kopeloff ’s
modification of the Gram stain (10).
Confirmation of GBS was achieved using catalase, Lansfield’s
grouping (DRO585A, Oxoid, Basingstoke), esculin hydrolysis,
and CAMP (Christie, Atkins and Munch-Peterson) tests.
PCR
DNA extraction was based on a procedure described by
Sambrook et al. (11) and the extracts separated in 0.8% (w/v)
agarose gels. Primers designed for the PCR amplification of the
universal bacterial and GBS-specific 16S rRNA genes are listed
in Table 1. A standard 50 µl PCR reaction solution contained
1 × PCR amplification buffer (10 × buffer contained 200mM
Tris pH 7.6, 100mMKCL, 100mM (NH4)2 SO4, 20mMMgSO4,
1% (w/v) Triton X-100), 0.2mM each of dATP, dCTP, dGTP, and
dTTP, 0.5µM of each primer, 1U of Taq DNA polymerase, and
10 ng template DNA.
After the initial heating step of 94◦C for 4min, cycles totalling
30 were run under the following conditions: denaturing at 94◦C
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TABLE 1 | Oligonucleotide specific primers used in this study for the amplification of the universal bacterial and GBS specific 16S rRNA genes.
Primers Nucleotide sequences (5′-3′) Position (16S rRNA gene) Annealing temp. Specificity References
E9F (forward) GAGTTTGATCCTGGCTCAG 9–27 50◦C Universal (12)
U1510R (reverse) GGTTACCTTGTTACGACTT 1,510–1,492 50◦C Universal (13)
Sag 40 (forward) CGCTGAGGTTTGTGTTTACA 40–61 60◦C Bacteria (14)
Sag 445 (reverse) CACTCCTACCAACGTTCTTC 445–465 60◦C Bacteria
for 30 s, primer annealing at 50◦C for 30 s and extension @
72◦C for 1min 30 s and final extension at 72◦C for 10min. The
universal bacterial 16S rRNA gene primer pair of E9F (12) and
U1510R (13) was used to amplify the nearly complete 16S rRNA
gene. Amplified products were separated on 0.8% agarose gels
using electrophoresis in 0.5 × TBE buffer. The products were
stained with ethidium bromide and visualized under UV, using
a transilluminator.
GBS specific primers (Sag 40 and Sag 445) were used for PCR
amplification under the following conditions: A pre–PCR step at
94◦C for 2min, initial denaturation at 94◦C for 45 s followed by
35 cycles of three temperature cycles involving denaturation at
95◦C for 30 s, annealing at 60◦C for 1min, extension at 72◦C
for 2min, followed by a final extension at 72◦C for 10min.
The presence of each PCR product was then verified using
electrophoresis in 1% agarose gel and stained with ethidium
bromide. GBS template DNA was used as a positive control and
no target DNA was added to the negative control.
Serotyping
GBS serotyping of the capsular polysaccharide antigens I-IX
was achieved using a latex agglutination typing kit (Hemolytic
Streptococcus Group B typing kit, Statens Serum Institut,
Denmark). A colony of GBS was suspended and incubated
overnight in 5ml of THB (Todd-Hewitt broth). Approximately
10 µl of the bacterial suspension was added to the latex
suspension on the circle card and mixed by gentle shaking for
a few seconds. Serotype designation was determined by a strong
agglutination reaction within 5–10 s. Any agglutination after 30 s
was not considered positive. If no designation could be made, the
isolate was deemed non-typeable.
Antimicrobial Susceptibility
Antimicrobial susceptibility was performed using the Kirby-
Bauer disk diffusion method and results interpreted according
to the Clinical Laboratory Standards Institute guidelines (15).
Pure colonies from each individual isolate were suspended in
5ml of saline. The inoculum was adjusted to the turbidity of a
0.5 McFarland standard and fresh culture suspensions (100 µl)
were evenly spread on Mueller-Hinton agar plates containing
5% sheep blood. After aseptically placing the antibiotic discs on
the surface of the spread plates, the plates were anaerobically
incubated at 37◦C overnight. The following eight antibiotic discs
were used: Penicillin G (PG) 1 Unit; Clindamycin (CD) 2 µg;
Gentamicin (GM) 10 µg; Fusidic Acid (FC) 10 µg; Erythromycin
(E) 5 µg; Trimethoprim (TM) 1.25 µg; Sulphamethoxazole
(SMX) 25 µg; Tetracycline (T) 10 µg. Post incubation, sensitivity
was determined by measuring the zones of inhibition from the
edge of the disk to the edge of the inhibition zone using a ruler.
Cultures showing no zones of inhibition were interpreted as
resistant.
Statistical Analysis
Data were analyzed using the Statistical Package for the Social
Sciences (SPSS) for windows version 19.0. The Chi square test
was used to determine the associations between two categorical
variables, but when the number in a cell was< 5, Fisher exact test
was applied. A p < 0.05 determined significance.
RESULTS
Detection of GBS
Lancefield grouping confirmed that 57 GBS isolates were
obtained from the agar and broth cultures of 50/301 (16.6%)
mothers. Comparison of agar and broth cultures showed no
difference in isolation of GBS, while all of the isolates which
were GBS culture-positive, were also positive by PCR. There was
no significant difference between GBS isolated from the vagina
(26/57) and the rectum (23/57) in this study. Twenty—three
samples with negative vaginal cultures were positive by their
corresponding anorectal samples, while GBS was isolated from
8 mothers by both vaginal and rectal samples.
Universal bacterial primers E9F and U1510R showed that
the DNA was suitable for PCR amplification and aided in
determining the amount of metagenomic DNA to be used (5 ng)
in all PCR experiments.
The PCR product amplified with GBS-specific forward and
reverse primers (Sag 40 and Sag 445) and viewed on a 1% agarose
gel, yielded the expected band size of 405 bp.
Study Population and GBS Colonization
Although mothers from Mowbray and Khayelitsha showed
similar rates of GBS colonization (36 and 32% respectively),
significant differences in colonization rates were noted when
Mitchells Plain (24%) and Guguletu (8%) mothers were included
in the comparison (Table 2).
The mean age of the study population was 28.8 (±5.2) years
and their ages ranged between 17 and 42 years (Table 2). GBS
colonization was highest amongst mothers in the 26–30 year age
group (24%).
Most women (53.2%) reported their marital status as
unmarried and 44.52% reported being married. No response
to this question was received from the remaining 2.33%
(Table 2). There was no significant difference between the
two groups for GBS colonization with 52% of unmarried
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TABLE 2 | Study population and GBS colonization.
Variables/Categories Frequency
(%) n = 301
Mothers with GBS
(%) n = 50
Significance
Location of the MOU p < 0.001
Mowbray 90 (29.9%) 18 (36.0%)
Khayelitsha 74 (24.6%) 16 (32.0%)
Mitchells Plain 86 (28.6%) 12 (24.0%)
Guguletu 51 (16.9%) 4 (8.0%)
Age groups (years) p = 0.613
17–25 81 (27%) 15 (30%)
26–30 107 (36%) 17 (34%)
31–35 72 (24%) 10 (20%)
36–40 26 (8.8%) 5 (10%)
≥41 7 (2.3%) 2 (4.0%)
Missing 8 (2.6%) 1 (2.0%)
Marital status p = 1.000
Married 134 (44.5%) 21 (42%)
Unmarried 160 (53.2%) 26 (52%)
Missing 7 (2.33%) 3 (6%)
Education p = 0.499
Primary school (G1–G7) 14 (4.7%) 2 (4.0%)
High school(G8–12) 274 (91.0%) 48 (96.0%)
University 10 (3.3%) 0 (0%)
Missing 3 (1.0%) 0
Race p = 1.000
Black (African) 149 (49.5%) 16 (32%)
Colored (mixed race) 41 (13.6%) 1 (2.0%)
White 0 0
Missing 111 (36%) 33 (66.6%)
Employment p = 0.925
Yes 118 (39.2%) 19 (38%)
No 180 (59.8%) 31 (62%)
Missing 3 (1%)
Personal hygiene p = 0.950
Bath 72 (24.1%) 13 (26.0%)
Hand wash 207 (68.7%) 34 (68.0%)
Shower 18 (6.0%) 2 (4.0%)
Douching 1 (0.3%) 1 (2.0%)
Missing 3 (0.9%)
Smoking p = 0.446
Yes 41 (13.6%) 9 (18.0%)
No 260 (86.4%) 41 (82.0%)
Alcohol
Yes 29 (9.6%) 4 (8%) p = 0.798
No 272 (90.4%) 46 (92%)
HIV status p = 0.440
Positive 74 (24.6%) 15 (30%)
Negative 201 (66.8%) 31 (62%)
Missing 26 (8.6%) 4 (8.0%)
mothers being GBS positive compared with 42% unmarried
mothers.
Themajority of participants indicated that they had completed
high school (91%) with <5% having primary school education
and only 3.3% having had tertiary education (Table 2). Three
(1%) failed to reveal their educational background but were
able to read and write. The higher rate of GBS colonization
amongst the high school group (96%) may be attributed to them
constituting the majority of participants in the study.
The sample group comprised of mostly black (African) and
mixed race (Colored) mothers, the majority of whom (59.8%)
were unemployed (Table 2). A large number (36%) refused to be
categorized into a particular race group and 1% did not respond
to the question on employment. While it would appear that
GBS occurred most frequently amongst the African group (32%)
compared with the Colored group (2%), many of both groups
were assigned to the “missing” group (66.6%) for the reason
mentioned above, thus complicating the interpretation of this
data.
Hand washing of the body using a basin was the most
frequently reported means of hygiene practice (68.7%), followed
by bathing (24.1%), and shower (6.0%). Only 1 mother (0.3%)
reported douching (Table 2). GBS prevalence was highest
amongst those who reported hand washing (68%), followed by
bathing (26%).
Smoking and consumption of alcohol while pregnant were
reported by 13.6 and 9.6% respectively, (Table 2) with those
reporting neither smoking (41%) nor drinking (46%) testing
negative for GBS.
HIV positivity (HIV+) was reported by 24.6% of the mothers,
with 66.8% being HIV-negative (HIV–) and 8.6% either ignorant
of their status or unwilling to disclose it. GBS colonization
was higher in the HIV- mothers (62%) than in the HIV+
mothers (30%), (Table 2) but this difference was not statistically
significant (p > 0.05).
Latex agglutination identified six different serotypes
(Figure 1). Serotype V predominated (66.6%) with 17.5 and
38.5% isolated from HIV+ and HIV– mothers, respectively, and
the HIV status of the remaining 10% not reported (Figure 2).
Serotype III followed (21.05%), with no difference in prevalence
between HIV+ and HIV– mothers (Figure 2). Only 1 (1.75%)
isolate belonged to each of serotypes Ia, II, IV, and IX in our
study (Figure 1), with the HIV status of the mother with
serotype Ia not disclosed and serotypes II, IV, and IX isolated
from HIV– mothers only (Figure 2). No significant difference
in serotype prevalence was observed between HIV+ and HIV–
mothers (p > 0.05). One woman (HIV–) harbored more than
1 serotype of GBS, namely serotypes IV and V. No strains
belonging to serotypes Ib, VI, VII, and VIII were found in
any of the isolates in this study. Serotyping was not possible
in 3 cases (5.3%), and were thus defined as non-typeable
(NT). In eight cases where GBS was cultured from both rectal
as well as vaginal samples, serotyping resulted in identical
findings for all of the paired samples, except for three. The
remaining three women were colonized with two different
serotype combinations, namely, serotypes III/IX, serotypes
IV/V, and serotypes III/V from the vaginal and anorectal swabs,
respectively.
Antibiotic Susceptibility
Fifty-six of the fifty-seven GBS isolates (98%) were susceptible
to clindamycin and erythromycin and 96% (55/57) were
susceptible to penicillin G. Only 2% (1/57) showed susceptibility
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FIGURE 1 | Distribution of capsular antigen types among GBS culture positive isolates from pregnant women in the Western Cape.
FIGURE 2 | Serotype distribution according to reported HIV status.
to tetracycline (T) and trimethoprim (TM) (Figure 3). Total
resistance (100%) to fusidic acid was demonstrated and
98% (56/57) were resistant to tetracycline and trimethoprim
(Figure 3). Ninety-five percent of the isolates (54/57) were
resistant to sulphamethoxazole, and 93% were resistant to
gentamicin (Figure 3).
Examination of the susceptibility profiles of the GBS
serotypes are summarized in Table 3. GBS serotypes Ia, II,
IX, and the three non-typeable strains showed susceptibility
to clindamycin, erythromycin, and penicillin G only. Serotype
III was susceptible to clindamycin, erythromycin, penicillin
G, and sulphamethoxazole. Serotype IV was susceptible to
clindamycin, erythromycin, penicillin G, sulphamethoxazole,
and trimethoprim. GBS serotype V showed susceptibility
to penicillin, erythromycin, clindamycin with resistance to
tetracycline, SMX, and TM.
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FIGURE 3 | Proportions of the responses of the 57 GBS culture positive isolates tested against eight different antibiotics: penicillin G (PG), clindamycin (CD),
gentamicin (GM), fusidic acid (FC), erythromycin (E), trimethroprin (TM), sulphamethoxazole (SMX), and tetracycline (T).
DISCUSSION
A report of invasive GBS disease in South Africa between 2004
and 2008 revealed an overall rate of neonatal GBS disease in
the Western Cape as 0.53–0.67/1,000 live births (16). Neonatal
GBS infection may be prevented by identifying and treating
pregnant women who carry GBS or who are at highest risk
of transmitting the bacteria to newborns. One recommended
approach for preventing the transmission of GBS from mothers
to neonates is to screen pregnant women by culture of combined
vaginal and rectal regions at 35–37 weeks of gestation and to
treat empirically those with positive cultures or risk factors for
disease transmission. Collection of samples during the later stages
of pregnancy is more representative of GBS colonization during
labor.
In the present study, we followed the CDC guidelines (8)
for sample collection and culture and found an overall GBS
prevalence of 16.6%, compared with prevalence rates of 25,
30, and 30.9% reported in similar studies from South Africa
(17–19). These differences may be attributed to several factors
including ethnicity and socio-economic standards. To our
knowledge, this is the first reported study of GBS serotype
antimicrobial susceptibility from the Western Cape region. The
aforementioned South African studies were conducted in areas
inhabited by different Black (African) tribal groups and although
our study reported Black participants as constituting the majority
of our study group, many of the participants (36%) refused to
be categorized by race, thereby introducing a bias. Historically,
the Western Cape was home to the indigenous people of the
region (Khoisan) and along with slaves brought from the East
by European settlers, this region is predominantly inhabited by
people of mixed race who previously, under Apartheid were
classified as “Colored” (a term considered by many to be
derogatory) and now fall under the generic “Black” category,
which includes all race groups other than White. Because we
were ethically bound to respect their refusal to be assigned to any
particular race group against their will, we recorded them in the
“missing” data, regardless of their appearance.
Low socio-economic status may be associated with the level
of education, access to preventive health care and poor personal
and environmental hygiene. Many of the Black people included
in this study came from informal settlements with undesirable
housing and ablution facilities, which could account for the
higher prevalence of GBS in this group, particularly since the
majority reported hand basin body washing (which facilitates
translocation of GBS) as their practice of personal hygiene.
Although the location of the MOU (Midwife Obstetrics Unit)
showed a significant association with GBS colonization, race
(probably due to the uncategorised persons) did not. Also of note,
is that the Mowbray MOU serves both race groups. Personal
hygiene, employment, level of education, marital status, and age
showed no significant association with GBS colonization.
A prevalence rate similar to this study (16.5%) was reported
from Germany (20) and 17.2% reported from the Netherlands
(21). Lower GBS prevalence (3.2%) was reported from Argentina
(22), Turkey (8.0%) (23), China (8.2%) (24), Mozambique (1.8%)
(25), India (2.3%) (26), and Nigeria (10.7%) (27). The higher
prevalence rates (25, 30, and 30.9%) reported in the other South
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African studies [(17–19), respectively], fall within the range
reported from other parts of Africa such as 20.9% in Ethiopia
(28), 23% in Tanzania (29), and 31.6% in Zimbabwe (30). Studies
from Iran (31), Brazil (32), and Switzerland (33) also reported
prevalence rates of 22.7, 24, and 21%, respectively.
Variations between different countries could be due to
multiple factors including time of sampling (i.e., during
pregnancy or at delivery), sampling site (vaginal only vs. vaginal
plus anorectal) and detection techniques (enriched selective vs.
enriched media and /or PCR) as well as maternal socio-economic
and other personal demography (34, 35). In their systematic
review and meta-analyses of maternal GBS colonization world-
wide, (35) reported an overall prevalence of 15% regardless
of sample collection or microbiological techniques used. After
adjusting for sampling and microbiological methods, the overall
prevalence increased to 18%, thereby demonstrating the risk of
underestimation when doing comparative studies.
Previous reports indicated that while GBS were isolated from
only rectal specimens in some cases and from vaginal specimens
in other cases, swabbing both the vagina and rectum was found
to increase the yield substantially compared with sampling either
the vagina or the rectum alone (26). Eight women tested positive
for GBS in both vaginal and rectal sites in this study and 5 of the
8 women had identical isolates in both sites, with the remaining
3 women colonized with two different serotype combinations.
Had we excluded rectal samples from our study, it would have
resulted in false negative results in 40% of cases. We observed
that the increased recovery from the rectal samples was largely
due to the incubation in selective enriched broth media for 24 h
prior to plating onto enriched agar. Conversely, a study by (36)
compared different cultural methods and reported poor recovery
of GBS from rectal swabs using selective broth enrichment. The
fact that GBS was sometimes isolated from only one site and not
the other shows how imperative it is to sample both anatomical
sites (vagina and rectum) when screening for GBS carriage in
pregnant women.
Maternal HIV status did not significantly affect GBS
colonization, nor did smoking or alcohol consumption in this
study. Whether or not HIV positivity contributes to GBS
colonization remains inconclusive. A recent study from Nigeria
(27) reported an overall prevalence of 10.7% GBS, with increased
GBS colonization in HIV-positive (15.5%) compared to HIV-
negative (6.0%) mothers, while HIV infection was not considered
as a risk factor for GBS colonization in a study from USA
(37), although age, ethnicity/race, alcohol, and tobacco showed
highly significant relationships. A South African study also
reported no maternal risk for increased GBS colonization in
HIV+ pregnant women (38) although there have been reports
of infants born of HIV+ mothers being at risk for invasive GBS
disease (39). Another South African study which examined the
effect of maternal HIV infection on immunoglobulin G serotype
specific-capsular (1a, 1b, III, and V) antibody along with GBS
surface protein maternal antibodies and transplacental transfer
to their neonates, revealed that after adjusting for overall and
serotype-specific GBS colonization, maternal age and parity,
the cord-maternal ratio was significantly lower for serotypes
1a (p < 0.0001) and III (p = 0.027) in HIV+ compared to
HIV– mother-neonate dyads, supporting the hypothesis of an
increased risk for neonatal GBS infection with reduced protective
antibodies (40).
The above comparison of GBS serotypes detected in HIV+
and HIV– mothers in Soweto and surrounding areas in South
Africa (40) showed that serotypes III and Ia were more prevalent
in HIV– mothers (40.7 and 59.1%, respectively), than in HIV+
mothers (13.6 and 29.6%, respectively), while in Brazil, serotypes
Ib (34.9%) and Ia (25.6%) predominated in HIV+ women
(41). Our study showed no significant differences in serotype
distribution between the HIV+ and HIV– mothers for serotypes
III and V, although serotypes II, IV, and IX were found in HIV-
mothers only and not in HIV+mothers.
The distribution of GBS serotypes not only differs from one
country to another but also between provinces within the same
country, with changes in prevalence over time (24, 42). A recent
global survey reported that serotypes Ia, Ib, II, III, and V account
for 98% of GBS serotypes detected, with variations reported for
different regions (35). A similar meta-analysis of GBS maternal
disease (43), listed serotype Ia as the most prevalent (31%),
followed by III (27%), V(19%), Ib(14%), and II(5%). Serotypes
1a and III are reported to account for the majority of invasive
cases of GBS (4, 44), while other studies (42, 45) reported serotype
V as the most important serotype in invasive disease. In this
study, 6 different serotypes of GBS were identified with serotype
V predominating, followed by serotype III. Of the 8 women who
tested positive for GBS in both vaginal and rectal sites in this
study, 5 had identical isolates in both sites, while the remaining 3
were colonized with two different serotype combinations, each
of 2 combinations including either serotype III or serotype
V (i.e., serotype combinations III/IX, IV/V) and 1 with both
III/V. Serotype III GBS strains are considered to account for the
majority of infections in neonates worldwide (46), with invasive
strains reported in Nairobi (47) and Soweto, South Africa (45).
Serotype III was also the most prevalent (29.7%) in another study
conducted in Pretoria, South Africa (18), followed by serotypes
Ia (25.8%), IV (10.9%), and Ib (8.6%). Serotypes Ib, VI–VIII
were not present in our study nor were VI–VIII found in the
study of (18). The South African study which examined the
effect of maternal HIV infection on immunoglobulin G serotype
specific-capsular (1a, 1b, III, and V) antibody along with GBS
surface protein maternal antibodies and transplacental transfer
to their neonates, revealed that after adjusting for overall and
serotype-specific GBS colonization, maternal age and parity, the
cord-maternal ratio was significantly lower for serotypes 1a (p <
0.0001) and III (p= 0.027) in HIV+ compared to HIV– mother-
neonate dyads, suggesting an increased risk for neonatal GBS
infection with reduced protective antibodies (40).
Three isolates (5%) were non-typeable in the present study,
while only 0.7% of isolates were non-typeable in the Pretoria
study (18). In the absence of human error, non-typeability might
be explained if the isolate has an insertion or a mutation in
genes that are essential for capsule expression (48), resulting
in a non-encapsulated variant or, if the isolate produces an
uncharacterized polysaccharide for which antibodies are not
yet available (i.e., a new serotype). The multiplex PCR method
of (49) yields good sensitivity and specificity and enables the
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characterization of all known GBS serotypes, thereby reducing
the rate of detection of non-typeable isolates. However, due to
financial constraints, we were unable to apply this technique and
report on the latex agglutination method instead.
Just as different serotypes predominate in different population
groups, so do their antimicrobial profiles. GBS susceptibility has
frequently been reported to ampicillin, cefazolin, erythromycin,
imipenem, norfloxacin, penicillin, and vancomycin (32).
Penicillin G remains the antibiotic of choice for the intrapartum
prophylaxis for GBS, with erythromycin and clindamycin used
as alternatives for those allergic to penicillin (26). Antibiotic
resistance patterns of 57 GBS isolates (from 50 mothers) were
tested in this study for their susceptibility to eight different types
of antibiotics that have been recommended for the eradication of
carriage and treatment of invasive GBS diseases. Results showed
that few were resistant to penicillin (5%), erythromycin (2%),
and clindamycin (2%) compared to resistance frequencies of
21.1% and 17.2% reported for erythromycin and clindamycin
in other studies (50, 51). Although strains resistant to penicillin
have been described in previous studies, they remain rare
(52, 53). Resistance to clindamycin and erythromycin is on the
increase and along with amoxicillin, have not been successful in
reducing adverse pregnancy outcomes (54). This resistance has
been attributed to specific serotypes.
Serotypes III and V are reported as the most
resistant serotypes with resistance to erythromycin,
trimethroprim/sulphamethoxazole (TM/SMX), clindamycin
and tetracycline reported (32, 55, 56). In the present study,
serotype III and V demonstrated resistance to tetracycline,
TM/SMX, with susceptibility to most of the other antimicrobials
tested, as did Ia, II, and IX.
Strategies to prevent neonatal GBS infection include the
elimination of exposure to GBS, chemoprophylaxis and vaccines.
Intrapartum chemoprophylaxis has greatly reduced the risk of
neonatal infection in women who carry GBS (5), but despite
these measures, GBS remains a leading cause of infectious
neonatal morbidity worldwide. The Centers for Disease Control
recommend that only mothers with a history of previous PTD
should be treated with antibiotics if found to have vaginosis or
vaginitis, since previous PTD is a powerful indicator of risk for
PTD (8).
All the GBS strains isolated in the present study were
resistant to fusidic acid, while others demonstrated resistance
to TM/SMX (98%), tetracycline (98%), and gentamicin (93%).
Resistance of GBS to tetracycline in our study population
was similar to the results observed in other studies (32,
57). In our study, susceptibility to sulphamethoxazole was
found in only three women, two of whom were HIV
positive. In Brazil, resistance to tetracycline, clindamycin,
and trimethroprim/sulphamethoxazole has been reported in
asymptomatic GBS carriers (32).
A strength of this study is that to our knowledge it is the first
to report on the antimicrobial resistance of GBS serotypes in the
Western Cape as well as serotype differences in HIV+ vs. HIV–
mothers. Limitations of the study include the relatively small
sample number, reluctance of some participants to reveal their
racial or HIV status, low income settings biased toward urban
areas thereby eliminating a comparison with rural or advantaged
socio-economic groups, and failure to follow up on neonates
born of these mothers.
GBS culture is labor intensive with the possibility of mixed
cultures resulting in the overgrowth of competitive species and
incubation time. Molecular diagnostic techniques such as PCR
have the advantage of rapidly identifying bacteria which are
difficult to grow and identifying newly emerging strains of
bacteria. The benefit of rapid reporting of bacteria in pregnant
women can significantly impact their pregnancy outcomes and
reduce mortality rate, while allowing for a simpler and more
efficient prevention programme which is speedy, sensitive, and
precise. Thus, PCR offers a good alternative to culture in
the absence of susceptibility testing, with 100% sensitivity and
specificity reported in the present study when compared with
culture.
CONCLUSION
In conclusion, the results of our study differ considerably from
studies in other regions of South Africa as well as in other
parts of the world, with differences in serotype distribution and
antimicrobial susceptibility possibly serving as a basis for GBS
guidelines for South Africa. Our results stress the importance
of epidemiological updates, particularly for those with penicillin
allergies. More studies are needed to accurately estimate the
global burden of GBS especially in developing countries (30).
Improved knowledge of the prevalence of GBS in pregnant
women would lead to a greater understanding of EOD and LOD
potential.
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